Triumvira Immunologics Strengthens its Leadership Team with Three Accomplished Life Sciences Executives
Retrieved on:
木曜日, 7月 20, 2023
Amgen, Stanford University, MBA, Employment, Acquisition, Patient, Diversity, Inclusion, Principal, Compensated emancipation, Corporate development, Boston Consulting Group, Orexigen Therapeutics, Business development, University, Therapy, Arena Pharmaceuticals, American InterContinental University, Lonza, Organization development, Research, Strategic planning, Gilead, Coulter, Corporation, Knowledge, Growth, Amylin Pharmaceuticals, III, Genome, Business, Whitehead, University of Miami, Reflexive relation, Genome Research, Human, Economics, BA, Human resources, Federal Reserve Board of Governors, TAC, Pharmaceutical industry, Management, Biochemistry, Pomona College, Cain (Italian band)
Robert F. Williamson, III is a seasoned biotech executive with more than 20 years of experience building and leading innovative biotechnology companies.
Key Points:
- Robert F. Williamson, III is a seasoned biotech executive with more than 20 years of experience building and leading innovative biotechnology companies.
- Mr. Williamson has successfully led multiple companies through significant growth, partnerships, financing rounds, IPOs, and successful acquisitions.
- Jeffrey Erickson is a life sciences executive with more than 20 years of business development, investor relations, and strategic planning experience leading numerous deals, M&A transactions and R&D collaborations.
- Additionally, Mr. Erickson worked on the sequencing of the human genome at the Whitehead Institute/MIT Center for Genome Research (Broad Institute).